Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunocore Holdings plcIMCR · Entity 4544 | HEAD OF R&D | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunocore Holdings plc
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,859 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-17 · Exercise / conversion · Acquired 11,824 · Balance 11,824 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Row 2 · 2026-02-18 · Sale · Disposed 5,965 · Balance 5,859 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 35,473 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Exercise / conversion · Disposed 11,824 · Balance 35,473 F4: Each RSU represents a contingent right to receive one Ordinary Share. F5: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs").
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Each RSU represents a contingent right to receive one Ordinary Share.
F5: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 5,965 | $32.35 | $192,967.75 |
DisclosureSEC source: 0001955244-26-000002 · form4-02192026_050203.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,859 F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2 · shares: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionRestricted Share Units · Derivative | 11,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001955244-26-000002 · form4-02192026_050203.xml · derivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,473 Underlying: Ordinary Shares · 11,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share. F5 · derivative.exercise_date: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F5 · derivative.expiration_date: On February 17, 2025, the Reporting Person was granted 47,297 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 11,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001955244-26-000002 · form4-02192026_050203.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 572 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,832 Underlying: Ordinary Shares · 572 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 572 | $40.14 | $22,960.08 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 572 | $17.46 | $9,987.12 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 31,341 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · derivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,404 Underlying: Ordinary Shares · 31,341 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 31,341 | $40.26 | $1,261,788.66 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.44 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 31,341 | $17.46 | $547,213.86 |
DisclosureSEC source: 0001955244-25-000015 · form4-12082025_041211.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 5,521 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,745 Underlying: Ordinary Shares · 5,521 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 5,521 | $40.09 | $221,336.89 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 5,521 | $17.46 | $96,396.66 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 69,404 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · derivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,266 Underlying: Ordinary Shares · 69,404 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 69,404 | $40.12 | $2,784,488.48 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 69,404 | $17.46 | $1,211,793.84 |
DisclosureSEC source: 0001955244-25-000013 · form4-12012025_041201.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 18,020 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,670 Underlying: Ordinary Shares · 18,020 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 18,020 | $40.03 | $721,340.60 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 18,020 | $17.46 | $314,629.20 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · derivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,690 Underlying: Ordinary Shares · 100 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 100 | $40.00 | $4,000.00 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 100 | $17.46 | $1,746.00 |
DisclosureSEC source: 0001955244-25-000011 · form4-11262025_091110.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 61,849 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000008 · form4-10022025_041002.xml · derivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,790 Underlying: Ordinary Shares · 61,849 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 61,849 | $35.23 | $2,178,940.27 |
DisclosureSEC source: 0001955244-25-000008 · form4-10022025_041002.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 61,849 | $17.46 | $1,079,883.54 |
DisclosureSEC source: 0001955244-25-000008 · form4-10022025_041002.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · derivative · entry 7 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,639 Underlying: Ordinary Shares · 200 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 200 | $35.01 | $7,002.00 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 200 | $17.46 | $3,492.00 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 22,532 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,839 Underlying: Ordinary Shares · 22,532 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 1,300 | $36.31 | $47,203.00 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 21,232 | $35.63 | $756,496.16 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,300 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $36.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 22,532 | $17.46 | $393,408.72 |
DisclosureSEC source: 0001955244-25-000005 · form4-09162025_040906.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 19,081 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · derivative · entry 7 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 221,371 Underlying: Ordinary Shares · 19,081 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 19,081 | $36.28 | $692,258.68 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 19,081 | $17.46 | $333,154.26 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 31,338 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,452 Underlying: Ordinary Shares · 31,338 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 1,200 | $36.77 | $44,124.00 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $36.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 30,138 | $36.12 | $1,088,584.56 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 20:10 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 31,338 | $17.46 | $547,161.48 |
DisclosureSEC source: 0001415889-25-024359 · form4-09122025_040901.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:18 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantRestricted Share Units · Derivative | 47,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004605 · form4-02192025_090204.xml · derivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,297 Underlying: Ordinary Shares · 47,297 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:18 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 129,518 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001415889-25-004605 · form4-02192025_090204.xml · derivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,518 Underlying: Ordinary Shares · 129,518 shares Expires 2035-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 36,509 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · derivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,790 Underlying: Ordinary Shares · 36,509 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 1,200 | $70.45 | $84,540.00 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 5 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.42 to $70.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 10,937 | $69.73 | $762,637.01 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 4 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.26 to $70.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 7,472 | $68.84 | $514,372.48 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 3 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,137 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 16,900 | $67.61 | $1,142,609.00 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 2 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,609 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.08 to $68.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 36,509 | $17.46 | $637,447.14 |
DisclosureSEC source: 0001415889-24-006079 · form4-03012024_040305.xml · nonDerivative · entry 1 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionEmployee Share Option (Right to Buy) · Derivative | 54,938 | $0.00 Strike: $17.46 | $0.00 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · derivative · entry 10 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,299 Underlying: Ordinary Shares · 54,938 shares Expires 2028-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F8 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 3,394 | $71.97 | $244,266.18 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 8 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.85 to $72.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 25,944 | $71.32 | $1,850,326.08 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 7 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,394 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.84 to $71.8307 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 21,152 | $70.42 | $1,489,523.84 |
DisclosureSEC source: 0001415889-24-005720 · form4-02282024_040201.xml · nonDerivative · entry 6 Berman David M · CIK 0001955244 · HEAD OF R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,338 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.835 to $70.8248 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.